Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study

被引:0
|
作者
Aziza Nassar
Daniel W. Visscher
Amy C. Degnim
Ryan D. Frank
Robert A. Vierkant
Marlene Frost
Derek C. Radisky
Celine M. Vachon
Ruth A. Kraft
Lynn C. Hartmann
Karthik Ghosh
机构
[1] Mayo Clinic,Department of Laboratory Medicine and Pathology
[2] Mayo Clinic,Department of Cancer Biology
[3] Mayo Clinic,Division of Anatomic Pathology
[4] Mayo Clinic,Department of Surgery
[5] Mayo Clinic,Division of Biomedical Statistics and Informatics
[6] Mayo Clinic,Division of Oncology Research
[7] Mayo Clinic,Division of Epidemiology
[8] Mayo Clinic,Division of Nephrology and Hypertension
[9] Mayo Clinic,Division of Medical Oncology
[10] Mayo Clinic,Division of General Internal Medicine
来源
关键词
Benign breast disease; Breast cancer; Cancer risk; Fibroadenoma; Mayo Clinic benign breast disease cohort;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study is to examine the breast cancer risk overall among women with simple fibroadenoma or complex fibroadenoma and to examine the association of complex fibroadenoma with breast cancer through stratification of other breast cancer risks. The study included women aged 18–85 years from the Mayo Clinic Benign Breast Disease Cohort who underwent excisional breast biopsy from 1967 through 1991. Within this cohort, women who had fibroadenoma were compared to women who did not have fibroadenoma. Breast cancer risk (observed versus expected) across fibroadenoma levels was assessed through standardized incidence ratios (SIRs) by using age- and calendar-stratified incidence rates from the Iowa Surveillance, Epidemiology, and End Results registry. Analyses were performed overall, within subgroups of involution status, with other demographic characteristics (age, year of biopsy, indication for biopsy, and family history), and with histologic characteristics, including overall impression [nonproliferative disease, proliferative disease without atypia (PDWA), or atypical hyperplasia]. Fibroadenoma was identified in 2136 women [noncomplex, 1835 (85.9 %); complex, 301 (14.1 %)]. SIR for noncomplex fibroadenoma was 1.49 (95 % CI 1.26–1.74); for complex fibroadenoma, it was 2.27 (95 % CI 1.63–3.10) (test for heterogeneity in SIR, P = .02). However, women with complex fibroadenoma were more likely to have other, concomitant high-risk histologic characteristics (e.g., incomplete involution and PDWA). In analyses stratified by involution status and PDWA, complex fibroadenoma was not an independent risk marker for breast cancer. Complex fibroadenoma does not confer increased breast cancer risk beyond other established histologic characteristics.
引用
收藏
页码:397 / 405
页数:8
相关论文
共 50 条
  • [21] NSAID use and breast cancer risk in a retrospective cohort of women with benign breast disease
    Degnim, Amy
    Vierkant, Robert
    Winham, Stacey
    Frost, Marlene
    Visscher, Daniel
    Carter, Jodi
    Kaggal, Suneetha
    Cunningham, Julie
    Allers, Teresa
    Hoskin, Tanya
    Heinzen, Ethan
    Vachon, Celine
    Knutson, Keith
    Knutson, Keith
    Radisky, Derek
    Sherman, Mark
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Validation of the BCSC model within the Mayo Benign Breast Disease Cohort
    Frank, Ryan D.
    Vachon, Celine M.
    Winham, Stacey J.
    Vierkant, Robert A.
    Frost, Marlene H.
    Radisky, Derek C.
    Visscher, Daniel W.
    Degnim, Amy C.
    CANCER RESEARCH, 2017, 77
  • [23] The Mayo Clinic Breast Cancer Book
    Fox, Bette-Lee
    LIBRARY JOURNAL, 2012, 137 (14) : 121 - 121
  • [24] The Role of Smoking in Breast Cancer Development: An Analysis of a Mayo Clinic Cohort
    Croghan, Ivana T.
    Pruthi, Sandhya
    Hays, J. Taylor
    Cha, Stephen
    Johnson, Ruth E.
    Kosel, Marianne
    Morris, Richard
    Hurt, Richard D.
    BREAST JOURNAL, 2009, 15 (05): : 489 - 495
  • [25] Attenuation of breast cancer risk in benign breast disease
    Bottrell, Alyssa
    Kapke, Alissa
    Lu, Mei
    Wolman, Sandra
    Worsham, Maria
    CANCER RESEARCH, 2008, 68 (09)
  • [26] Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study
    Skriver, Charlotte
    Cronin-Fenton, Deirdre
    Borgquist, Signe
    Viuff, Jakob Hansen
    Alkner, Sara
    Ryden, Lisa
    Laenkholm, Anne-Vibeke
    Manjer, Jonas
    Bengtsson, Ylva
    Frederiksen, Kirsten
    Friis, Soren
    Mellemkjaer, Lene
    BRITISH JOURNAL OF CANCER, 2025,
  • [27] PROGESTOGEN USE AND DECREASED RISK OF BREAST-CANCER IN A COHORT STUDY OF PREMENOPAUSAL WOMEN WITH BENIGN BREAST DISEASE
    PLUBUREAU, G
    LE, MG
    SITRUKWARE, R
    THALABARD, JC
    MAUVAISJARVIS, P
    BRITISH JOURNAL OF CANCER, 1994, 70 (02) : 270 - 277
  • [28] BENIGN BREAST DISEASE AND CANCER RISK
    BIANCHI, S
    PALLI, D
    GALLI, M
    ZAMPI, G
    CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 1993, 15 (03) : 221 - 242
  • [29] A PROSPECTIVE-STUDY OF BENIGN BREAST DISEASE AND THE RISK OF BREAST-CANCER
    LONDON, SJ
    CONNOLLY, JL
    SCHNITT, SJ
    COLDITZ, GA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (07): : 941 - 944
  • [30] Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort
    Sherman, Mark E.
    Vierkant, Robert A.
    Masters, Matthew
    Radisky, Derek C.
    Winham, Stacey J.
    Degnim, Amy C.
    Vachon, Celine M.
    Patel, Alpa V.
    Teras, Lauren R.
    CANCER PREVENTION RESEARCH, 2023, 16 (03) : 175 - 184